Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  European Neuropsychopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 9169309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of reboxetine and desipramine on the kinetics of the pupillary light reflex.

  1995cited by this paper
• Guidelines on psychotropic drugs for the EC. Committee for Proprietary Medicinal Products. European Economic Community.

  1994cited by this paper
• Side-effects of Antidepressants

  1993cited by this paper
• Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression.

  1990cited by this paper
• The Toxicity of Antidepressants

  1989cited by this paper
• A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder.

  1985cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• A COMPREHENSIVE PSYCHOPATHOLOGICAL RATING SCALE

  1978cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Organocatalyzed Protecting-Group-Free Total Synthesis of (S,S)- and (S,R)-Reboxetine, an Antidepressant Drug.

  2022cites this paper
• A review of antidepressant-induced urinary hesitancy: a focus on levomilnacipran ER including two case presentations(5633)

  2016cites this paper
• Individualized Pharmacological Treatment of Depressive Disorders State of the Art and Recent Developments

  2014cites this paper
• A review of the adverse effects and safety of noradrenergic antidepressants

  2013influential citation
• Für jeden Patienten den optimalen Wirkstoff finden

  2012cites this paper
• Antidepressants and body weight: a comprehensive review and meta-analysis.

  2010cites this paper
• Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study

  2010cites this paper
• Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.

  2010cites this paper
• A highly sensitive HPLC method with automated on-line sample pre-treatment and fluorescence detection for determination of reboxetine in human plasma.

  2010cites this paper
• Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: a prospective long-term open-label study

  2010cites this paper
• Getting the balance right: Established and emerging therapies for major depressive disorders

  2010cites this paper
• Antidepressants and Falls in the Elderly

  2009cites this paper
• Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[18F]FMeNER-D2

  2009cites this paper
• Nicotinic receptor-based therapeutics and candidates for smoking cessation.

  2009cites this paper
• Depression in adults: drug and physical treatments.

  2007cites this paper
• Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: a human whole-body PET study

  2007cites this paper
• Combined treatment with reboxetine in depressed patients with no response to venlafaxine: a 6-week follow-up study

  2007cites this paper
• Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities

  2006cites this paper
• Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study

  2006cites this paper
• A review on hyponatremia associated with SSRIs, reboxetine and venlafaxine

  2006cites this paper
• The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.

  2006cites this paper
• The promises and pitfalls of reboxetine.

  2006cites this paper
• Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?

  2005cites this paper
• Efficacy and Tolerability of Reboxetine in Depressive Patients Treated in Routine Clinical Practice

  2005cites this paper
• Asymmetric synthesis of (+)-(S,S)-reboxetine via a new (S)-2-(hydroxymethyl)morpholine preparation.

  2005cites this paper
• Reboxetine as an Optional Treatment for Hyperkinetic Conduct Disorder: A Prospective Open-Label Trial

  2005cites this paper
• An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study.

  2005cites this paper
• Dose-response relationship of recent antidepressants in the short-term treatment of depression

  2005cites this paper
• Depression in HIV-infected patients: allopathic, complementary, and alternative treatments.

  2004cites this paper
• Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects.

  2004cites this paper
• Australian and New Zealand Clinical Practice Guidelines for the Treatment of Depression

  2004cites this paper
• Effects of Reboxetine on Sleep and Nocturnal Cardiac Autonomic Activity in Patients with Dysthymia

  2004cites this paper
• Australian and New Zealand clinical practice guidelines for the treatment of depression.

  2004cites this paper
• Mirtazapine Decreases Stimulatory Effects of Reboxetine on Cortisol, Adrenocorticotropin and Prolactin Secretion in Healthy Male Subjects

  2004cites this paper
• Depression in the elderly: new concepts and therapeutic approaches

  2004cites this paper
• Pharmacogenetics of monoamine transporters.

  2003cites this paper
• Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients

  2003cites this paper
• An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder.

  2003cites this paper
• Determination of Serum Reboxetine Enantiomers in Patients on Chronic Medication With Racemic Reboxetine

  2003cites this paper
• Bipolar Depression

  2003cites this paper
• Selektive Hemmung der Noradrenalin-Wiederaufnahme als humanes Modell für orthostatische Intoleranz

  2003cites this paper
• The Antidepressant Efficacy of Reboxetine in Patients with Severe Depression

  2003cites this paper
• Differential effects of chronic antidepressant treatments on micro- and delta-opioid receptors in rat brain.

  2002cites this paper
• Effects of Reboxetine on Anxiety, Agitation, and Insomnia: Results of a Pooled Evaluation of Randomized Clinical Trials

  2002cites this paper
• Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression

  2002cites this paper
• Effect of repeated treatment with reboxetine on the central alpha 1-adrenergic and dopaminergic receptors.

  2002cites this paper
• The role of noradrenaline and selective noradrenaline reuptake inhibition in depression.

  2002cites this paper
• Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin.

  2002cites this paper
• The neuropharmacology of centrally-acting analgesic medications in fibromyalgia.

  2002cites this paper
• Treating depression: the beyondblue guidelines for treating depression in primary care. "Not so much what you do but that you keep doing it".

  2002cites this paper
• No effect of a noradrenergic reuptake inhibitor on performance in trained cyclists.

  2002cites this paper
• Reboxetine: a preliminary report on its use through the Special Access Program.

  2002cites this paper
• Determination of reboxetine, a recent antidepressant drug, in human plasma by means of two high-performance liquid chromatography methods.

  2002cites this paper
• Late-Life Depression: Rationalizing Pharmacological Treatment Options

  2002cites this paper
• Reboxetine, a New Noradrenaline Selective Antidepressant, Is at Least as Effective as Fluoxetine in the Treatment of Depression

  2002cites this paper
• Reboxetine: attenuation of intravenous nicotine self-administration in rats.

  2002cites this paper
• Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors.

  2002cites this paper
• Tamsulosin as an effective treatment for reboxetine-associated urinary hesitancy

  2001cites this paper
• Third-Generation Antidepressants

  2001cites this paper
• Depression and dysthymia.

  2001cites this paper
• The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system

  2001cites this paper
• Effect of repeated treatment with reboxetine on the central alpha1-adrenergic system.

  2001cites this paper
• The effects of reboxetine on autonomic and cognitive functions in healthy volunteers

  2001cites this paper
• Reboxetine-induced hypomania.

  2001cites this paper
• Reboxetine in the maintenance therapy of depressive disorder in the elderly: a long‐term open study

  2000cites this paper
• Problems with currently available antidepressants.

  2000cites this paper
• Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents

  2000cites this paper
• Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.

  2000cites this paper
• Reboxetine in the treatment of bulimia nervosa: a report of seven cases

  2000cites this paper
• Norepinephrine dysfunction in depression.

  2000cites this paper
• Clinical efficacy of reboxetine in major depression.

  2000cites this paper
• Reboxetine: A Selective Norepinephrine Reuptake Inhibitor for the Treatment of Depression

  2000cites this paper
• Reboxetine in a neuroendocrine challenge paradigm: evidence for high cortisol responses in healthy volunteers scoring high on subclinical depression.

  2000cites this paper
• Reboxetine, the first selective noradrenaline reuptake inhibitor antidepressant: Efficacy and tolerability in 2613 patients

  2000cites this paper
• Pharmacotherapy of depression and mixed states in bipolar disorder.

  2000cites this paper
• Urinary retention with reboxetine-fluoxetine combination in a young man.

  2000cites this paper
• Narcolepsy: genetic predisposition and neuropharmacological mechanisms. REVIEW ARTICLE.

  2000cites this paper
• Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.

  2000cites this paper
• Treatment of severe depression.

  2000cites this paper
• Neue Antidepressiva im Vergleich zu klassischen Trizyklika

  2000cites this paper
• Psychopharmacology of Depression in the Next Millennium

  1999cites this paper
• Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial.

  1999cites this paper
• Reboxetine: a review of efficacy and tolerability.

  1999cites this paper
• Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.

  1999cites this paper
• Recent advances in antidepressant drug therapy.

  1999cites this paper
• Pharmacological profile of reboxetine, a representative of new class of antidepressant drugs, selective noradrenaline reuptake inhibitor (NARI), given acutely.

  1999cites this paper
• Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism.

  1999cites this paper
• Reboxetine versus fluoxetine: an overview of efficacy and tolerability.

  1998cites this paper
• Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review.

  1998cites this paper
• Noradrenergic versus serotonergic antidepressants: predictors of treatment response.

  1998cites this paper
• Treatment of depression--newer pharmacotherapies.

  1998cites this paper
• Doxazosin for reboxetine-induced urinary hesitancy

  1998cites this paper
• Selecting an Antidepressant for Use in a Patient with Epilepsy

  1998cites this paper
• Chairman's overview. The place of reboxetine in antidepressant therapy.

  1998cites this paper
• The clinical pharmacologic profile of reboxetine: does it involve the putative neurobiological substrates of wellbeing?

  1998cites this paper
• Reboxetine: additional benefits to the depressed patient.

  1997cites this paper
• The enhancement of social functioning as a therapeutic principle in the management of depression.

  1997cites this paper